Drug-induced liver injury due to antibiotics

References

• Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–489.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Spanish Group for the Study of Drug-Induced Liver Disease. Gastroenterology. 2005;129:512–521.
   PubMed Web of Science ®Google Scholar
• de Valle M, Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther. 2006;24:1187–1195.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Drug Induced Liver Injury Network (DILIN). Gastroenterology. 2008;135:1924–1934.
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396–2404.
   PubMed Web of Science ®Google Scholar
• Idilman R, Bektas M, Cinar K, et al. The characteristics and clinical outcome of drug-induced liver injury: a single-center experience. J Clin Gastroenterol. 2010;44:128–132.
   PubMed Web of Science ®Google Scholar
• Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340–1352.
   PubMed Web of Science ®Google Scholar
• Björnsson B, Bergqvist A, Jerlstad P, et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40:1095–1101.
   PubMed Web of Science ®Google Scholar
• Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52:2065–2076.
   PubMed Web of Science ®Google Scholar
• Wei G, Bergquist A, Broome U, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med. 2007;262:392–401.
   Web of Science ®Google Scholar
• Mindikoglu AL, King D, Magder LS, et al. Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States. J Pediatr. 2011;158:802–807.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63:590–603.
   PubMed Web of Science ®Google Scholar
• Dolson JE. Hepatotoxicity due to antibiotics. Clin Liver Dis. 2007;11:549–561.
   PubMedGoogle Scholar
• Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 2011;66:1431–1446.
   PubMed Web of Science ®Google Scholar
• Stine JG, Lewis JH. Hepatotoxicity of antibiotics a review and update for the clinician. Clin Liver Dis. 2013;17:609–642.
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–455.
   PubMed Web of Science ®Google Scholar
• Hussaini SH, Despott EJ, O'Brien CS, et al. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol. 2007;19:15–20.
   PubMed Web of Science ®Google Scholar
• Thomson JA, Fairley CK, Ugoni AM, et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust. 1995;162:638–640.
   PubMed Web of Science ®Google Scholar
• Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3–13.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138:2246–2259.
   PubMed Web of Science ®Google Scholar
• Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29:364–372.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Chaalsani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661–670.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity. Hepatology 2006;44:850–856.
   PubMed Web of Science ®Google Scholar
• deLemos AS, Ghabril M, Rockey DC, et al. Amoxicillin-clavulanate-induced liver injury. Digestive Diseases and Sciences 2016;61:2406–2416.
   PubMed Web of Science ®Google Scholar
• Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988;8:599–606.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–2048.
   PubMed Web of Science ®Google Scholar
• de Boer YS, Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15:103–112.
   PubMed Web of Science ®Google Scholar
• Bhat G, Jordan J, Jr, Sokalski S, et al. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol. 1998;27:74–75.
   PubMed Web of Science ®Google Scholar
• Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4:73–96.
   PubMedGoogle Scholar
• Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44:1581–1588.
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Kalaitzakis E, Klintbert AV, et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:79–85.
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50:511–517.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147:96–108.
   PubMed Web of Science ®Google Scholar
• Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy's law. Gastroenterology. 2014;147:20–24.
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Kleiner D, Gu J, et al. Clinical presentation and outcomes of bile duct loss caused by drugs and dietary supplements. Hepatology. 2016. doi: 10.1002/hep.28967. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Olsson R, Wiholm BE, Sand C, et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15:154–161.
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58:71–80.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49:2001–2009.
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Niklasson A, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003–2009.
   PubMed Web of Science ®Google Scholar
• Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10:1018–1023.
   PubMed Web of Science ®Google Scholar
• Lammert C, Niklasson A, Saha C, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51:615–620.
   PubMed Web of Science ®Google Scholar
• Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388–396.
   PubMed Web of Science ®Google Scholar
• Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology. 1999;117:1181–1186.
   PubMed Web of Science ®Google Scholar
• O’Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47:717–720.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Alonso A, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004;39:1603–1612.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338–347.
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816–819.
   PubMed Web of Science ®Google Scholar
• Ghabril M, Fontana R, Rockey D, et al. Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol. 2013;47:553–558.
   PubMed Web of Science ®Google Scholar
• Davies MH, Harrison RF, Elias E, et al. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol. 1994;20:112–116.
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Kleiner DE, Ghabril M, et al. Identification and Characterization of Cefazolin-Induced Liver Injury. Dig Dis Sci. 2016;61:2406–2416.
   PubMed Web of Science ®Google Scholar
• Turillazzi E, D'Errico S, Neri M, et al. A fatal case of fulminant hepatic necrosis following sevoflurane anesthesia. Toxicol Pathol. 2007;35:840–845.
   PubMed Web of Science ®Google Scholar
• Lin J, Moore D, Hockey B, et al. Drug-induced hepatotoxicity: incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients. Liver Int. 2014;34:576–582.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Olsson R, Remotti H. Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. Am J Gastroenterol. 2000;95:3662–3664.
   PubMed Web of Science ®Google Scholar
• Elliott TR, Symes T, Kannourakis G, et al. Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF? BMJ Case Rep. 2016. doi: 10.1136/bcr-2015-213189
   Google Scholar
• Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011;9:517–523.
   Google Scholar
• Paterson JM, Mamdani MM, Manno M, et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012;184:1565–1570.
   PubMed Web of Science ®Google Scholar
• Alshammari TM, Larrat EP, Morrill HJ, et al. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. Am J Health Syst Pharm. 2014;71:37–43.
   PubMed Web of Science ®Google Scholar
• Kaye JA, Castellsague J, Bui CL, et al. Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. Pharmacotherapy. 2014;34:336–349.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25:1411–1421.
   PubMed Web of Science ®Google Scholar
• Longo G, Valenti C, Gandini G, et al. Azithromycin-induced intrahepatic cholestasis. Am J Med. 1997;102:217–218.
   PubMed Web of Science ®Google Scholar
• Chandrupatla S, Demetris AJ, Rabinovitz M. Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci. 2002;47:2186–2188.
   PubMed Web of Science ®Google Scholar
• Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 2015;13:369–376.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Gunnarsson BI, Gröndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13:602–608.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Lindberg J. Olsson Rolf. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol. 1997;32:390–395.
   PubMed Web of Science ®Google Scholar
• Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology. 2009;49:250–257.
   PubMed Web of Science ®Google Scholar
• Savard S, Desmeules S, Riopel J, et al. Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Am J Kidney Dis. 2009;54:e17–e20.
   PubMed Web of Science ®Google Scholar
• De Bus L, Depuydt P, Libbrecht L, et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6:322–326.
   PubMedGoogle Scholar
• Kraleti S, Soultanova I. Pancytopenia and lactic acidosis associated with linezolid use in a patient with empyema. J Ark Med Soc. 2013;110:62–63.
   PubMedGoogle Scholar